See more : Max Heights Infrastructure Limited (MAXHEIGHTS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Scopus BioPharma Inc. (SCPS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scopus BioPharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Cadiz Inc. (0HS4.L) Income Statement Analysis – Financial Results
- Sunita Tools Limited (SUNITATOOL.BO) Income Statement Analysis – Financial Results
- Northamerican Energy Group Corporation (NNYR) Income Statement Analysis – Financial Results
- Canadian Pacific Railway Limited (CP) Income Statement Analysis – Financial Results
- Xi’an ChenXi Aviation Technology Corp., Ltd. (300581.SZ) Income Statement Analysis – Financial Results
Scopus BioPharma Inc. (SCPS)
About Scopus BioPharma Inc.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.68M | 15.02M | 7.42M | 463.11K | 277.54K |
| General & Administrative | 9.03M | 12.61M | 2.73M | 2.23M | 408.43K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.03M | 12.61M | 2.73M | 2.23M | 408.43K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.71M | 27.63M | 10.16M | 2.69M | 685.96K |
| Cost & Expenses | 11.71M | 27.63M | 10.16M | 2.69M | 685.96K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 774.68K | 706.45K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.73K | 1.50K | 1.44K | 664.00 | 161.14K |
| EBITDA | -11.71M | -27.63M | -10.15M | -2.69M | -685.96K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.71M | -27.63M | -10.16M | -2.69M | -685.96K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 681.21K | -706.45K | 0.00 | 0.00 |
| Income Before Tax | -11.71M | -26.95M | -10.86M | -2.69M | -685.96K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -105.05K | 774.68K | 706.45K | 1.00 | -847.11K |
| Net Income | -11.61M | -27.73M | -11.57M | -2.69M | -685.96K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.55 | -1.61 | -0.87 | -0.18 | -0.05 |
| EPS Diluted | -0.55 | -1.61 | -0.87 | -0.18 | -0.05 |
| Weighted Avg Shares Out | 21.09M | 17.25M | 13.36M | 14.98M | 14.98M |
| Weighted Avg Shares Out (Dil) | 21.09M | 17.25M | 13.36M | 14.98M | 14.98M |
Scopus BioPharma Announces Closing of $9 Million Follow-On Public Offering
Scopus BioPharma Announces Completion of Clinical Lot Manufacture
Scopus BioPharma Announces Appointment of Additional Directors
Scopus BioPharma Announces Closing of Initial Public Offering
SCPS Stock: 14 Things to Know About the Scopus BioPharma IPO
Scopus BioPharma Stock Price Surged Over 300% In Public Debut
Newly Listed Scopus Biopharma Soars Over 500%: What Investors Need to Know
Scopus BioPharma Announces Pricing of Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports